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ABSTRACT
Vav family members function as remarkable scaffold proteins that exhibit both 
GDP/GTP exchange activity for Rho/Rac GTPases and numerous protein-protein 
interactions via three adaptor Src-homology domains. The exchange activity is 
under the unique regulation by phosphorylation of tyrosine residues hidden by 
intra-molecular interactions. Deletion of the autoinhibitory N-terminal region results 
in an oncogenic protein, onco-Vav, leading to a potent activation of Rac GTPases 
whereas the proto-oncogene barely leads to transformation. Substitution of conserved 
residues of the SH2-SH3 adaptor region in onco-Vav reverses oncogenicity. While 
a unique substitution D797N did not affect transformation induced by onco-Vav, 
we demonstrate that this single substitution leads to transformation in the Vav1 
proto-oncogene highlighting the pivotal role of the adaptor region. Moreover, we 
identified the cell junction protein β-catenin as a new Vav1 interacting partner. We 
show that the oncogenicity of activated Vav1 proto-oncogene is associated with a 
non-degradative phosphorylation of β-catenin at residues important for its functions 
and its redistribution along the cell membrane in fibroblasts. In addition, a similar 
interaction is evidenced in epithelial lung cancer cells expressing ectopically Vav1. 
In these cells, Vav1 is also involved in the modulation of β-catenin phosphorylation. 
Altogether, our data highlight that only a single mutation in the proto-oncogene Vav1 
enhances tumorigenicity. 
INTRODUCTION
The Vav1 proto-oncogene has a restricted 
hematopoietic expression and exhibits both GTP/GDP 
exchange activities (GEF) for Rho family GTPases and 
adaptor functions within signalling complexes [1, 2]. Two 
other genes, Vav2 and Vav3 belong to the same family of 
signalling effectors and share high structural similarities 
and properties with Vav1. Unlike Vav1, Vav2 and Vav3 
have an ubiquitous expression [3, 4]. Vav proteins display 
a number of characteristic structural domains with 
homology for: Calponin (CH), Dbl (DH), Pleckstrin (PH) 
and Src (SH2 and SH3) altogether with acidic residues-
rich (AcR) and cysteine-rich (CR) motives. These 
domains mediate interactions with membrane receptors, 
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signalling intermediates, cytoskeleton related proteins 
and nuclear factors [5]. Vav proteins also exhibit a unique 
regulation of the GEF activity through receptor-mediated 
phosphorylation of tyrosine residues (pY) present in the 
AcR domain [6].
The initial characterization of Vav1 consisted in a 
truncated version of the proto-oncogene (wt-Vav1) with 
deletion of the first 66 residues within the CH domain 
that resulted in a transforming protein (onco-Vav) when 
expressed in fibroblasts [7]. Further deletion including 
the AcR motive (1-186 amino acids) or substitution of 
phenylalanine for the regulatory tyrosines abrogated the 
phosphorylation dependency of the transforming activity 
[8, 9]. To date, these oncogenic forms of Vav1 have never 
been found in neoplasms. Nevertheless, ectopic expression 
of Vav1 is detected and involved in the pathophysiology 
of neuroblastoma, pancreatic adenocarcinoma, melanoma, 
lung and breast cancer [10-14]. In pancreatic tumours, 
Vav1 regulates cell-cycle progression, proliferation, 
transformation and invasive migration through its 
interaction with dynamin 2 [10, 15]. Vav1 is also 
expressed in a majority of breast carcinoma where its 
activity is dependent on the p53 status of the cells since 
it induces apoptosis in wild-type p53 cells but contributes 
to proliferation in p53-/-  cells [14]. Moreover, mutation 
within the N-terminal regulatory region correlates with 
central nervous system immune-mediated disease [16]. 
Critical roles have also been attributed to Vav2 and Vav3 
in breast or skin cancers and in metastatic dissemination 
[17-19]. Altogether, these data indicate that Vav proteins 
display a pivotal role in tumorigenesis although not fully 
characterized.
The structural complexity and high similarities of 
Vav proteins have indicated both GTPase-dependent and 
GTPase-independent roles. Truncations of the inhibitory 
CH or AcR domains resulted in deregulated GEF activity, 
constitutive activation of Rho proteins and transformation 
[8, 20]. However, protein-protein interactions mediated by 
specific structural domains of Vav might also contribute 
to cellular transformation. In particular, the CR motif 
contributes to the stabilization of the DH domain and 
to an efficient GEF activity [21]. Intact SH2 and SH3 
domains are also critical for the transforming potential 
of onco-Vav; mutations of conserved residues within the 
SH2 domain of onco-Vav affect or abrogate oncogenicity 
due to the loss of association with tyrosine-phosphorylated 
proteins [22]. Similarly, mutations of conserved residues 
of the C-terminal SH3 domain reversed the transforming 
potential of onco-Vav; while mutation of a Vav-family 
specific residue in the carboxyl-terminal SH3 domain 
(D797) was unsignificant to onco-Vav oncogenicity and 
maintained the binding capacity to several interacting 
partners [23]. This region also contributes strongly to 
the intramolecular inhibition of Vav family proteins 
[24]. Moreover, not only Vav2 and 3 but also Vav1 
phosphorylation can promote Rho family activation 
in non-hematopoietic tissues following stimulation of 
several growth factor receptor tyrosine kinases [25-27]. 
These Vav-mediated mechanisms lead to reorganization 
of actin cytoskeleton and cell-cell contacts and increased 
motility [12, 28]. Notably, Vav2-mediated modulation of 
p120 catenin - E-cadherin clustering has been implicated 
in fibroblasts motility and in Rac-dependent activation of 
β catenin [29-31]. Therefore, ectopic expression of Vav1 
and its capacity to interact with specific proteins in non-
hematopoietic cells contribute likely to its transforming 
potential and to tumorigenesis.
In this study, we investigated whether alterations 
within the protein-protein interaction CSH3 domain might 
activate the transforming properties of the Vav1 proto-
oncogene. We identified D797 as one novel key residue 
controlling Vav1 oncogenicity, since its unique mutation 
confers transforming properties to Vav1 proto-oncogene. 
We also identified β-catenin as a new Vav1 interacting 
partner in fibroblasts and epithelial lung cancer cells. The 
transformation, which is dependent on Rac activation, is 
associated with the phosphorylation and the stabilization 
of β-catenin altogether with its relocation from junctional 
complexes to random membrane localization in fibroblasts. 
Our data provide novel insights on the mechanism of 
Vav1-regulated oncogenesis that involves cell-cell contact 
dysregulation.
RESULTS
Mutation of the specific aspartic acid 797 residue 
in Vav1 C-SH3 domain activates its transforming 
and tumorigenic potential
The C-terminal SH3 adaptor region of Vav1 contains 
several conserved residues present in Src, Grb2 or Abl 
SH3 domains but also unique residues specific for Vav 
family members (Figure 1a). We analysed a selection of 
Vav1 proto-oncogene CSH3 mutants: D797N, A789N and 
G830V, for their capacity to induce foci of transformed 
cells when expressed in NIH3T3 cells and compared them 
to onco-Vav (∆1-66). Interestingly, mutation of D797 
residue activates significant transformation potential, 
inducing foci similar albeit to a lesser extent than ∆1-66 
onco-Vav. Despite equivalent transfection efficiencies, 
as verified by the comparable amounts of G418-resistant 
clones obtained with the various constructs, none of the 
other mutants as well as wt-Vav1 induced transformed foci 
(Figure 1b, c and d). Immunoblot analysis confirmed that 
the transforming potential of the D797N mutant could not 
be ascribed to higher levels of protein expression. Two 
days after transfection or in established stable cell lines, 
D797N mutant and wt-Vav1 showed similar levels of 
expression and higher levels than onco-Vav that displayed 
the greatest transforming capacity (Figure 1e and f). 
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Kinetic analysis of the mutated proteins in the presence of 
cycloheximide validated the steady state levels observed 
in stable cell lines showing a weaker stability for A789N 
or G830V when compared to D797N, onco-Vav or wt-
Vav1 (Figure 1f and supplemental Figure S1). Moreover, 
we noticed higher levels of phosphorylated D797N and 
onco-Vav1 proteins compared to wt-Vav1 reflecting an 
increased activation of both mutants in these cell lines 
(Figure 1g).
Next, we compared the proliferative properties of 
stable cell lines expressing wt-Vav1, onco-Vav or D797N 
mutant. Higher proliferation rates and saturating densities 
were observed for transforming proteins-expressing cells 
while wt-Vav1-expressing cells exhibited an intermediate 
growth rate as compared to control with empty vector 
(Figure S2a). Unlike control or wt-Vav1, cells expressing 
onco-Vav and D797N overgrew the monolayer and 
proliferated beyond confluence (Figure S2a). Moreover, 
in reduced serum conditions, although wt-Vav1 or control 
cells showed poor proliferation rates, cells expressing 
onco-Vav and D797N lost high serum dependence 
(Figure S2b). Finally, loss of anchorage requirement was 
observed for onco-Vav or D797N expressing cells that 
displayed clonal expansion developed in semi-solid agar 
Figure 1: Transforming potential of the D797N Vav mutant. a. Sequence alignment of SH3 domains containing proteins. SH3 
domains of Src, Grb2 and Abl are used as a reference for Vav1-2-3 C-terminal SH3 domains. Conserved residues are in bold. Stars 
and double string indicate the mutated residues used in the study. b-c-d Focus formation assays. Two weeks after transfection with 
the indicated constructs, NIH3T3 cells were fixed, stained with Giemsa solution, observed using light microscopy (b, Nikon camera 
DXMI200F, magnification 20x) and the foci numbers were quantified (c). After selection with G-418, neo-resistant clones were counted 
relative to transfection with empty vector (d). Results are the mean of four independent experiments ± standard deviation. e-f. Vav1 proteins 
expression. Cell extracts from 48h transient transfections (e) or G418-selected stable cell lines (f) expressing the myc-tagged Vav1 proteins 
were analysed by immmunobloting with anti-myc Ab (upper panel). Loading controls were assessed by detection of actin and tubulin 
(lower panel). g Phosphorylation levels of Vav1 proteins in stable cell lines. Proteins were analysed by immmunobloting using phospho 
Tyr174-Vav1 antibody (upper panel) and anti-Vav1 antibody (lower panel).
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cultures (Figure 2a). In contrast, wt-Vav1 expressing cells 
engendered very few clones of reduced size. D797N-
transformed fibroblasts also acquired the capacity to 
generate tumours in Nu/Nu mice after subcutaneous 
injection as did onco-Vav and all animals injected with 
these cells developed tumours. The overall weight of the 
tumours generated by onco-Vav and D797N-expressing 
cells was highly above those generated by wt-Vav1 
or empty vector when present (Figure 2b). However, 
D797N-derived tumours showed a more heterogeneous 
size than did onco-Vav while wt-Vav1 expressing cells 
only generated small nodes (Figure 2c). Interestingly, 
Vav1 proteins extracted from the tumour cells exhibited 
activated pY174 at levels comparable to those observed 
in injected cells reflecting Vav1 activation (Figure 2c and 
1g).
Altogether these data demonstrate that one unique 
CSH3 specific substitution into Vav1 proto-oncogene 
confers activation to the protein leading to transformation 
and tumorigenesis.
Figure 2: Anchorage-independent growth and tumorigenic potential of the D797N Vav1 mutant. a. NIH3T3 stable cell 
lines were cultured in soft-agar medium as described in Methods. After 3 weeks, colonies were observed using light microscopy (Leica 
DMI6000, Camera MicroMAX 1300Y/HS, magnification 10x). b. The indicated NIH3T3 cells (106) were injected subcutaneously in Nu/Nu 
mice. Three weeks after injection, tumours were harvested and weighted. Means ±SD of 4 independent experiments performed in duplicate 
are indicated. The number of injected animals developing tumours is also indicated. c Imaging of the tumours and phosphorylation levels 
of Vav1 proteins from tumour cells. Proteins were analysed by immmunobloting using phospho Tyr174-Vav1 antibody (upper panel) and 
anti-Vav1 antibody (lower panel). Examples of the extracted tumours are shown on top of the western blot for the 3 constructs (2 images 
for D797N).
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Rac1 and RhoA GTPases-dependent pathways 
are required for D797N-induced transformation
The transforming activity of all N-terminal deleted 
Vav oncoproteins has been ascribed to uncontrolled 
GEF activity on GTPases of the Rho family [6, 9, 
20, 32]. Therefore, we investigated whether D797N-
induced transformation might similarly depend on Rho 
GTPases activation. Cell morphology and cytoskeleton 
organization of onco-Vav- or D797N-transformed 
cells suggested activation of the GTPases with typical 
formation of ruffles (lamellipodia and filipodia) (Figure 
3a; [33]). These cells also exhibited a large reduction of 
stress fibers that were abundantly present in control or 
wt-Vav1-expressing fibroblasts (Figure 3a, Pseudocolor 
and quantification of stress fibers and/or ruffles). Using 
pull-down experiments with a glutathione S-transferase 
(GST) fusion protein containing the Rac1 binding domain 
of p21protein-activated protein kinase 1 (PAK), we 
observed a significant activation of Rac1 GTPase in onco-
Vav and D797N-expressing cells and a faint activation in 
wt-Vav1-expressing cells. These results also confirmed 
the differential transforming potential of onco-Vav and 
D797N (Figure 3b). Additionally, overexpression of 
the dominant-negative form of Rac1, RacN17, strongly 
repressed foci formation for both constructs. Comparable 
repression was obtained using the dominant-negative form 
of RhoA, RhoN19, albeit to a lesser extent that might be 
attributed to a weaker expression of the GTPase (Figure 
3c). 
To explore downstream events mediating the 
transforming activity, we investigated the activation of 
c-jun NH2-terminal (JNK) and of stress-activated protein 
p38 (SAPK) kinases, two direct effectors of Vav and Rac/
Rho GTPases [32]. Immunoblot assay, using a specific 
antibody for phosphorylated Thr183/ Tyr 185 JNK1/2, 
demonstrated an enhanced activation upon expression 
of onco-Vav or D797N as compared to wt-Vav1 or 
control vector (Figure 4a). A weaker activation of p38 
SAPK was also detected in the transformed fibroblasts 
(Figure S3a). Activation of JNK kinases yielded to the 
phosphorylation of c-Jun, an important target involved in 
cell proliferation and tumorigenesis [34]. As demonstrated 
by immunoblotting with anti-phospho-Ser63 c-Jun, 
after incubation or not with the SP600125 specific JNK 
inhibitor, a strong JNK-dependent activation of c-Jun was 
found in onco-Vav- and D797N-expressing cells, while a 
weaker activation was noticed for wt-Vav1 (Figure 4b). 
Implication of JNK kinases in onco-Vav- and 
Figure 3: Rac1 and RhoA GTPases are effectors for D797N Vav1 mutant-induced transformation. a. Cytoskeleton 
analysis. The indicated stable NIH3T3 cells lines were observed using light microscopy (Leica DMI6000, Camera MicroMAX 1300Y/HS, 
magnification 20x, first left panel) or were immunostained with Alexa 647-conjugated-phalloidin (right and middle panels) and anti-Myc 
Tag Ab followed by Alexa 488-conjugated anti-mouse Ig Ab (Vav1, second left panel). Pseudocolor images indicate the intensity gradients 
of cytoskeleton labelling (right panel). Bar = 12µm. Confocal images were acquired with a BD Pathway 855 Bioimaging System with a 40x 
magnification and analyzed by ImageJ software. A line was drawn across at least 15 cells from each different clone and linescan profiles 
of fluorescence intensity were obtained using the Analyze-Plot profile function. The numbers of cells presenting the indicated profiles are 
indicated for each cell line under the plot. b Rac1 activation. Rac1 activity was assessed in stable NIH3T3 cell lines using GST-Pak1 pull-
down experiments (n=3). A representative experiment is shown (right panel). Cellular extracts were also analysed by immunoblottting for 
Rac1 and Vav1 expression (left panel) c. Rac1/RhoA are required for foci formation. NIH3T3 cells were transfected with Vav1 constructs 
altogether with empty, RacN17 or RhoN19 pRK5-myc based vectors as indicated. The number of foci was scored for each transfection. 
Columns represent the mean ± SD of 3 independent experiments performed in duplicate (left panel). Expression of Vav1, RacN17 and 
RhoN19 proteins was monitored by immunoblotting (right panel). 
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D797N-mediated transformation was further confirmed 
using the SP600125 specific inhibitor. As shown in Figure 
4c, addition of 10µM SP600125 completely prevented foci 
formation by both onco-Vav- and D797N-expressing cells. 
In contrast, addition of 15µM SB203580, a p38 SAPK 
inhibitor, only reduced by two fold the number of foci 
(Figure S3b). 
Altogether these results indicate that, similarly to 
onco-Vav-, D797N-mediated transformation involves the 
GEF activity toward Rac/Rho GTPases leading to typical 
cell morphology changes and to the subsequent activation, 
albeit to a lesser extent, of JNK-dependent pathways.
β-catenin is a molecular target of Vav1/JNK 
activation and a new Vav1 interacting partner
Next, we analysed downstream targets of the Rac/
JNK-mediated pathway that has proven relevant for 
cell-cell contacts and adherens junctions. Both Rac1 and 
JNK2 are involved in the dynamic regulation between 
the signalling activity and the structural function of 
the stable pools of β-catenin [31, 35-37]. Immunoblot 
analysis with antibodies recognizing either β-catenin or 
its triple phosphorylated form (Ser33/37/Thr41) showed 
Figure 4: The transforming potential of D797N Vav1 
implicates a JNK-dependent pathway. a-b. JNK1/2 and 
c-Jun phosphorylation analyses. Protein extracts from stable 
NIH3T3 cell lines were analysed by sequential immunoblotting 
with (a) anti-phospho-JNK (Thr183/Tyr185) and anti-JNK 
Abs; (b) anti-phospho-c-Jun (Ser63) and anti-c-Jun Abs. Fold 
increases of phospho-JNK1/2 and phospho-c-Jun in cells 
expressing wt-Vav1, onco-Vav and D797N compared to control 
vector were normalized to whole Jnk1/2 and c-Jun expression, 
respectively. Inhibition of c-Jun phosphorylation was monitored 
after 2h treatment (+) or not (-) with the JNK inhibitor SP600125 
(10µM). c. JNK activity is required for onco-Vav and D797N-
induced foci formation. Focus formation assays were performed 
with NIH3T3 cells transfected with the indicated constructs and 
0, 5, 10 or 20 µM of SP600125. Foci formation is calculated 
relative to untreated cells (100%). Results are means ± SD of 3 
independent experiments performed in duplicate.
Figure 5: β-catenin is a molecular target of Vav/JNK 
activation. a. β-catenin is a target of JNK. Total cell extracts 
from stable NIH3T3 cell lines cultured in the presence (+) or not 
(-) of SP600125 were analysed by sequential immunoblotting 
with the indicated Abs. Fold increase of phospho-β-catenin in 
cells expressing wt-Vav1, onco-Vav and D797N compared to 
control vector were normalized to whole β-catenin. b-c. Vav1 and 
β-catenin are interacting partners. b. Lysates from the indicated 
stable NIH3T3 cell lines were immunoprecipitated with anti-
Myc Tag Ab. Immune complexes (upper panels) or total extracts 
(lower panels) were analysed by sequential immunoblotting 
with the indicated Abs. c. GST-fusion proteins as described 
in the upper panel were incubated with NIH3T3 cell extracts. 
Interacting β-catenin was determined by immunoblotting. Total 
cell extract (Input) was used as a control for β-catenin expression 
and GST fusion proteins were detected using Ponceau red. GST-
SH* corresponds to D797N mutation introduced into GST-SH 
fusion protein.
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Figure 6: Vav1 influences β-catenin phosphorylation and subcellular localization. The indicated cell lines were analyzed using: 
a and d. Sequential western blotting with the indicated Abs for total cell extracts (a) or after subcellular fractionation between membrane, 
cytoplasmic and nuclear fractions (d). b. TCF/Lef-luciferase reporter activation was evaluated in 293T cells 48h after transfection with 
the indicated constructs and incubation (LiCl, grey bars) or not (NT, black bars) with 30 mM LiCl. Expression was calculated relative to 
levels detected in control cells. Results are means ±SD of three independent experiments performed in triplicates. c. Immunofluorescence 
microscopy after immunostaining with Alexa 647-conjugated anti-β-catenin (upper panel) and anti-Myc tag Ab followed by Alexa 
488-conjugated secondary Ab (Vav, lower panel). Fluorescence intensity of β-catenin labelling was analysed all along the membrane using 
the Analyze-Plot profile function (graphs in middle panel). Arrows indicate the peaks of intensity observed in the upper panel. 
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higher phosphorylation in cells expressing tranformants 
or wt-Vav1 as compared to empty vector (Figure 5a). 
Phosphorylation was not associated with an overall 
reduction of β-catenin levels as reported for GSK3-
mediated phosphorylation [38, 39]. In the presence 
of the JNK inhibitor, β-catenin phosphorylation was 
largely inhibited indicating the involvement of this 
kinase in a post-translational modification that does not 
trigger β-catenin for degradation (Figure 5a, 40). Thus, 
we explored a possible interaction between Vav1 and 
β-catenin. As shown in Figure 5b, β-catenin specifically 
co-precipitated with all Vav1 proteins. Using GST-fusion 
proteins containing either all three (GST-SH) or individual 
(NSH3, SH2 and CSH3) Src homology domains, we 
further restricted the interaction with β-catenin to the SH2 
domain of Vav1. No interaction was observed with the 
two GST-SH3 fusion proteins. Interestingly, the D797N 
mutation introduced into the GST-SH fusion protein 
(GST-SH*) did not affect Vav1 interaction with β-catenin 
(Figure 5c). Therefore, these results indicate that Vav1 
associates with β-catenin in a complex through its SH2 
domain.
Vav1 influences β-catenin phosphorylation and 
subcellular localization
Since subcellular localization and phosphorylation 
on particular residues of β-catenin are crucial events that 
modulate its different functions, we further investigated 
whether Vav1 proteins could have an impact on these 
modifications. Western blot analysis with anti pS675 
β-catenin, a residue phosphorylated by the JNK kinase 
[29, 40] confirmed increased phosphorylation in Vav1 
expressing cells, and more significantly with the two 
oncogenic forms. Similar increases of pY654- and non 
phosphorylated- β-catenin were also observed for all 
Vav1 expressing cells (Figure 6a). A non specific increase 
of all phosphorylated forms in these cells was ruled out 
by using anti pY142-, pS552 and pY489- β-catenin that 
remained with constant levels in all the transfectants (data 
not shown). 
Since phosphorylation of S675 and the non-
phosphorylated β-catenin have been implicated in 
the balance between membrane function and nuclear 
translocation of β-catenin, we sought to verify whether 
expression of Vav1 mutants could impact β-catenin 
transcriptional activity. Upon transient transfection of a 
luciferase reporter construct based on β-catenin-TCF/LEF 
transcriptional function we did not observe significant 
differences between the various Vav1 constructs in 293T 
cells. On the other hand, treatment with LiCl, a potent 
inhibitor of GSK3β−dependent degradation of β-catenin 
resulted in a substantial and comparable induction of the 
transcriptional response in all cases (Figure 6b).
 Next, we evaluated β-catenin distribution at the 
cell membrane. As expected, endogenous β-catenin was 
abundantly localized at the cell membrane in control cells 
with a clustered accumulation at the sites of adhesion 
and cell-cell contacts. Importantly, expression of Vav1 
proteins resulted in a redistribution of β-catenin all along 
the membrane with a decreased clustering. This peculiar 
reduction of the clustering of β-catenin was even more 
pronounced with the two oncogenic Vav1 proteins. Also, 
we noticed in several cells a significant cytoplasmic 
accumulation in association with perinuclear labelling 
(Figure 6c). These results were confirmed by cellular 
fractionation followed by western blot analysis. The 
accumulation of pS33/37/T41-β-catenin was detected in 
the cytoplasmic fraction with few nuclear translocation 
in onco-Vav-expressing cells only; while the non-
Figure 7: Vav1 interacts with β-catenin in lung epithelial 
cancer cell lines. a. Vav1 protein expression in pulmonary 
and lymphoid cell lines. Total cell extracts were analysed by 
sequential immunoblotting with the indicated Abs. b. Total cell 
extracts from the indicated cells were immunoprecipitated (IP) 
with anti-Vav1 Ab or control IgG. Immune complexes or total 
extracts (Input) were analysed by sequential immunoblotting 
with the indicated Abs. c. Η358 and Η441 cells were transfected 
with the indicated siRNA and proteins levels assessed 72 hours 
after transfection. Ratio between phospho-β-catenin and total 
β-catenin was calculated relative to transfection of control 
siRNA. 
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phosphorylated counterpart was consistently distributed 
between membrane and nucleus for all the cells (Figure 
6d). Furthermore, accumulations of pY654-β-catenin at the 
membrane and of pS675-β-catenin both at the membrane 
and in the nucleus confirmed the difference seen between 
the different cell lines in whole cell extract. Conversely, 
random localization of β-catenin at the membrane in 
onco-Vav and D797N-expressing cells (Figure 6c) was 
not associated with changes in the overall amounts of 
β-catenin in these fractions compared to control cells. 
Finally, substantial amounts of Vav1 proteins were also 
observed in the nuclear fraction (Figure 6d). 
Thus, these results support an impact of Vav1 
expression on certain phosphorylations and on structural 
function of β-catenin at the cell-cell contacts and adhesive 
complexes. Notably, a differential phosphorylation by 
wt-Vav1, and more importantly by the two oncogenic 
proteins, was observed on residues that are targets of 
Figure 8: Ectopic expression of Vav1 allows modulation of β-catenin in lung cancer cells. a. Total cell extracts from stable 
H358 cells expressing control vector only, wt-Vav1 or the D797N mutant were analysed by immunoblotting with the indicated Abs. Fold 
increase of phospho-Y654- and phospho-S675-β-catenin in cells expressing wt-Vav1 and D797N compared to control cells were normalized 
to total β-catenin. b. Wt-Vav1 and D797N expressing cells proliferation. 2.105 stable H358 cells (left panel) or transiently transfected A549 
cells (right panel) expressing the indicated constructs were seeded in 6-wells plate in duplicate and counted at the indicated times. Each 
value represents the mean of the cell number ± standard deviation from one representative experiment of a total of three. c. Morphology of 
H358 cells. Stable H358 cells expressing the indicated constructs were cultured below sub-confluence and photographed by phase contrast 
(magnification. 20x). d. Immunofluorescence analysis of β-catenin in H358 cell lines. The indicated stable H358 cell lines were analysed 
after anti-pS675β-catenin and Vav1 immunostaining (left panels) or anti- β-catenin and Vav1 immunostaining (right panel) by confocal 
microscopy.
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Vav1-dependent pathways.
Ectopic expression of Vav1 allows the modulation 
of β-catenin in lung cancer cells
The ectopic expression of Vav1 is observed in 
numerous non-hematopoietic cancer cells [10, 12, 13, 
41]. As shown in Figure 7a, H358 and H441, two human 
lung carcinoma epithelial cell lines exhibit substantial 
amounts of Vav1 proteins compared to a lymphoid cell 
line (Raji). Our results obtained in fibroblasts prompted us 
to figure out whether Vav1 interacts with β-catenin in these 
cells. We confirmed the interaction between endogenous 
Vav1 and β-catenin in both cell lines. Analyses of Vav1 
immunoprecipitates allowed also the specific detection 
of α-catenin and E-cadherin, two β-catenin well known 
partners at the cadherin-based adherens junctions (Figure 
7b, [40]. Remarkably, the two epithelial cell lines 
displayed pS33/37/T41β-catenin (Figure 7c). In order to 
confirm the impact of Vav1 expression on the stability 
and phosphorylation of β-catenin in these cells, we used 
RNA interference to reduce endogenous Vav1 expression 
or alternatively overexpression of wt-Vav1 or D797N. 
Transfection of Vav1 siRNA into H358 and H441 cells 
resulted in decreased levels of pS33/37/T41β-catenin 
as compared to control siRNA while no reduction of 
the overall β-catenin levels was observed (Figure 7c). 
This effect of Vav1 was further confirmed with stable 
overexpression of wt-Vav1 or D797N in H358 cells 
where higher levels of phosphorylation were detected in 
such conditions (Figure 8a). Moreover, we confirmed a 
differential impact of D797N compared to wt-Vav1 on 
pS33/37/T41-, pS675- and pY654-β-catenin intensities 
yet the mutant form was expressed at lower levels than 
wt-Vav1.
Next, the impact of these overexpressions on the 
proliferation rate and the cell morphology were evaluated. 
As shown in Figure 8b (left panel) H358 cells expressing 
D797N mutant exhibited a rapid overgrowth as compared 
to wt-Vav1 or control vector. Similarly, when transiently 
transfected with D797N mutant, A549 cells that do not 
express endogenous Vav1 (Figure 7a), showed as early 
as 72 hrs post transfection a proliferative advantage 
as compared to control cells (Figure 8b right panel). 
Morphological changes were also observed. While H358 
cells expressing wt-Vav1 presented with an intermediate 
shape, showing less protrusions and stretched morphology 
than vector-transfected cells, D797N appeared with round 
shaped cells forming multi-layers groups of cells. Finally, 
immunofluorescence analysis of H358 with anti-pS675 
β-catenin Ab indicated a more random localization at 
the membrane of the phosphorylated protein in wt-Vav1 
or D797N cells compared to control cells that kept a 
punctuated labeling at sites of cell-cell contact, whereas 
total β-catenin remained unchanged between the three cell 
lines (Figure 8d).
These results demonstrate that the expression of 
Vav1 contributes in cancer cells to the phosphorylation at 
specific residues of β-catenin with an advantage for the 
D797N mutant that demonstrated in fibroblasts higher 
GEF activity. These modifications of β-catenin participate 
to the modulation of its function at cell-cell junctions and 
to the subsequent alteration of cell shape and growth. 
Moreover, Vav1 interacts also with β-catenin partners in 
adherens junctions strongly suggesting a key role in cell-
cell adhesion.
DISCUSSION 
This study highlights the essential role of 
the adaptor region of Vav1 not only as a scaffold 
domain for immune receptors signalosomes but also 
as a tranformation potentiator. Using, in Vav1 proto-
oncogene, the unique mutation of an aspartic acid 
residue, specific for the Vav family of proteins, we show 
that alteration of the C-terminal SH3 domain activates 
the transforming capacity of the proto-oncogene. A 
previous study, addressing the role of the CSH3 domain 
in the transforming capacity of onco-Vav, showed that the 
D797N substitution did not abrogate the oncogenicity and 
was considered as unsignificant compared to mutations on 
conserved residues among SH3 domains [23]. Importantly, 
our results show that this single mutation, in the full-
length Vav1 proto-oncogene, is able to induce activation 
and consequently oncogenesis.
This gain of function mutation occurs on a charged 
residue that does not belong to the consensus residues 
required for the structural integrity of the SH3 domains 
[23, 42]. It is rather placed in a hinge section available 
for interaction with negatively charged residues of other 
domains or proteins. A previous study already showed 
that the mutation on this residue is not likely to affect 
the interaction with other partners [23]. We show here 
that the novel interaction with β-catenin is conserved 
with the mutant protein. Crystallographic resolution of 
the full-length molecule has not been reported so far; 
however, several mutational or biochemical approaches 
have given insights to the regulation of Vav functions 
through conformational changes occurring notably upon 
a stimulation process [9, 21, 24]. Alterations activating 
the transforming activity have been described for other 
SH-containing proteins and have been reported in human 
cancers. For example, mutations of the kinases Src and 
Abl or of the exchange factor Dbl in domains adjacent 
to their catalytic site greatly activate their oncogenic 
potential [43-45]. So far, oncogenicity of Vav1 has been 
ascribed to an activation of its GEF activity following 
the deletion of the autoinhibitory loop present at the 
N-terminus of the protein [6, 21, 46, 47]. This deletion 
allows further regulation of the GEF activity by 
phosphorylation of tyrosine residues present within the 
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acidic region [48]. These tyrosine residues are hidden 
by intra-molecular interactions that prevent the GEF 
activity [47-49]. Additional intramolecular folding was 
shown to be important for Vav functions [50]. Recently, 
an elegant mutational study demonstrated that the 
C-SH3 domain highly contributes to the formation of the 
autoinhibited state of the full length Vav1 proto-oncogene 
[24]. Among others, the D797 residue is mediating such 
regulatory intramolecular interactions and consequently, 
the D/N mutation should disrupt such a contact leading to 
potentiation of the GEF activity as seen in the Rac GTPase 
assay. This increased GEF activity is also evidenced by 
enhanced phosphorylated state of the D797N mutant 
compared to the wt-Vav1. 
One key finding of this work is the identification 
of a new partner for Vav1, β-catenin. The SH2-domain 
of Vav1 mediates this interaction likely by recognition of 
phosphorylated tyrosine residues of β-catenin. Multiple 
phosphorylated Ser/Thr or Tyr residues of β-catenin are 
involved in the regulation of the protein. In particular, 
several sequence motives contribute to conformational 
changes that lead to signalling functions or recognition 
by the proteasomal machinery for its degradation [40]. 
Our results show that Vav1 expression activates the Rac/
JNK pathway in fibroblasts and, its oncogenic mutations 
potentiate this activity. Activation of JNK induces 
phosphorylation and stabilization of β-catenin at sites 
also targeted by GSK-3β, an important component of the 
degradation complex together with Axin and APC [29, 
40, 51]. In this work we show that Vav1/JNK-dependent 
phosphorylation on both S675 and S33/37/T41 rather 
stabilizes β-catenin and its phosphorylated forms in 
different cellular compartments. Similar effects of JNK 
have been described in keratinocytes and in colon cancer 
cells together with an inhibitory role on the formation 
of clustered adhesive complexes with α-catenin and 
E-cadherin [29, 36, 37]. Expression of the oncogenic 
mutants in fibroblasts leads to redistribution of β-catenin 
along the membrane with a reduction of adhesion clusters 
and some translocation to the cytosol. These results 
suggest that Vav1 and its oncogenic forms can serve 
as adaptors and potentiators bridging JNK kinase with 
effector β-catenin that will modify cohesion at the cell-cell 
adhesion sites. We showed an association of Vav1 within 
the adherens junction complexes involving α-catenin and 
E-cadherin in epithelial cancer cell lines. In these cells we 
also evidence a potentiator role for Vav1, and moreover 
for the activated D797N mutant, in the phosphorylation of 
β-catenin at specific residues and some redistribution of 
β-catenin at the membrane along with modification of the 
cell shape. Interestingly, a recent work highlighted a role 
for Vav1 in Epithelial Mesenchymal Transition (EMT) 
in ovarian cancer [52] and it has been demonstrated that 
β-catenin might participate in this process [53]. Further 
work will figure out how Vav1 might contribute to the 
modulation of the assembly of adherens junctions. Besides 
Vav1, Vav2, a more ubiquitously expressed member of 
the family of adaptors, also interacts with components of 
the adhesion complex, e.g. through p120-catenin in SW-
480 colon cancer cells [54]. Particularly, Vav2 interacts 
with Ser-phosphorylated, Tyr-dephosphorylated cytosolic 
p120-catenin that has been released from the E-cadherin-
Wnt receptor complex at the cell membrane upon Wnt 
stimulation [30]. 
In other cellular processes, such as 
osteoblastogenesis, or in colon cancer cells, a Rac1/JNK2-
dependent phosphorylation of β-catenin was described at 
sites that regulate its nuclear accumulation and signalling 
function [31]. The transport of β-catenin to the nucleus 
represents an important regulation node for the balance 
between its adhesive and signalling properties [55]. Our 
biochemical fractionation and immunofluorescence 
analysis in fibroblasts showed an increased perinuclear 
β-catenin labelling in the presence of the transforming 
forms of Vav1 but a rather weak translocation to the 
nucleus for the pS33/37/T41 stabilized form and a more 
evident nuclear accumulation for pS675 β-catenin. In our 
experimental settings, in the presence of Vav1 oncogenic 
forms, we observed a Vav1-JNK dependent activation of 
c-Jun but we did not observe the transcriptional activation 
of β-catenin associated with its stabilization. However, 
we observed that the D797N mutant confers a growth 
advantage when overexpressed in lung cancer cells. We 
cannot rule out a putative Vav1-dependent cooperation 
between AP1 and β-catenin to regulate tumour progression 
and further work is needed to address this point [56, 57]. 
In light with the recent findings on Vav1 as a 
central regulator of invadopodia [15], our study reveals 
a new aspect of Vav1 functions when its deregulated 
expression favors the interaction with additional partners 
that leads to the alteration of signalling pathways involved 
in developmental processes or cell contact inhibition 
and that can ultimately result in growth advantage or 
tumorigenesis. Additionally, our results strengthen 
the importance of activating single point mutations in 
the C-SH3 domain that abrogate Vav1 autoinhibition, 
potentiate the GEF activity and consequently facilitate 
tumour progression. Since mutation on the adaptor protein 
can affect cell-contact inhibition, Vav seems an interesting 
target to modulate signalling during tumorigenesis. 
METHODS
Mammalian expression plasmids and GST fusion 
proteins
The pEF-neo expression plasmids encoding Myc-
tag human wt-Vav1 has been previously described [58]. 
Plasmids containing ∆1−66 onco-Vav and A789N, 
D797N and G830V mutants, were subcloned in pEF-neo 
Oncotarget2535www.impactjournals.com/oncotarget
expression vectors. Wt-vav1 and D797N mutant were also 
subcloned in pcDNA. pRK5 expression plasmids encoding 
Myc-tagged Rac1(17N) and RhoA(19N) were kindly 
provided by Dr. O. Dorseuil (Institut Cochin, U1016 
INSERM, Paris, France). PCR amplified N-terminal Src 
homology (NSH3), SH2 and CSH3 or whole Src (SH) 
domains of Vav were subcloned in pGEX-4T-1 or pGEX-
4T-3 (Pharmacia Biotech Inc.) 
Antibodies 
Antibodies for Myc-Tag, Vav1, JNK, p-JNK, p38, 
p-p38, lamin A/C, p-βcatenin S33/37/T41, Hsp70, P-c-Jun, 
c-jun, pY654-β-catenin, pS675- β-catenin, no-P- β-catenin 
and Alexa 647-conjugated anti-β-catenin were obtained 
from Cell Signalling Technology, Anti-β-catenin, anti-E-
cadherin, EEA1 Abs and anti-IgG control isotype were 
purchased from Becton Dickinson (BD), anti-α-catenin 
and anti-Tyr174 Vav1 from Santa-Cruz, and anti-β actin 
or anti-tubulin from Sigma. 
Cell culture, transfection and focus formation 
assay
NIH3T3 cells were cultured in DMEM 
supplemented with 10% Newborn Calf Serum (NCS; 
Invitrogen and PAA). For the focus formation assays, 
cells were cultured for 12-14 days after transfection with 
Lipofectamine and Reagent Plus (Invitrogen); medium 
was replaced every 2 or 3 days and was supplemented 
or not with JNK (SP600125) or P38 (SB203580) kinases 
inhibitors (Calbiochem). Foci were scored after Giemsa 
staining. Stable NIH3T3 cell lines expressing the 
various Vav proteins and vector control were selected 
in the presence of 1 mg/ml neomycin after transfection. 
Neomycin-resistant colonies were scored after 10-12 days 
of selection.
H358, H441 and A549 cell lines were maintained in 
RPMI and DMEM respectively, supplemented with 10% 
Foetal Bovine Serum (FBS; PAA). H358 and A549 cell 
lines were transfected with pcDNA constructs by using the 
Amaxa or JetPrime (Polyplus) following recommendation.
SiRNA control or targeting Vav1 were purchased 
from Dharmacon and transfected using JetPRIME reagent 
(Polyplus).
Anchorage-independent growth assay
NIH3T3 cells were cultured in DMEM-10% NCS 
containing 0,4% agar over a layer of DMEM-10% NCS 
containing 0.8% agar during 21 days. Growth medium was 
added every other week. 
Tumorigenic assay in Nude mice
Stable NIH3T3 cells lines were injected 
subcutaneously in Nu/Nu mice (1.106 cells). Development 
of tumours was monitored weekly. 
Protein stability assay using cycloheximide
4.105 cells were seeded in 6-well dishes 24h prior 
to treatment with 100 µM cycloheximide. Cells were 
harvested at different time points after drug addition (2-8 
hours). Stability of the Vav mutant proteins was evaluated 
by western blot.
Immunoprecipitation and western blot analyses
Protein extracts were prepared in Triton lysis buffer 
(50mM Tris-HCL [pH 7.5], 150mM NaCl, 10% glycerol, 
1mM EDTA, 0.1% Triton-X100) containing protease 
inhibitors (10 µg/ml aprotinin, 5 µg/ml leupeptin, 5 µg/ml 
pepstatin, 1mM phenylmethyl sulfonyl fluoride (PMSF), 
1mM DTT, 25mM β-glycerophosphate, 1mM sodium 
fluoride and 1mM Na3VO4). Proteins were separated by 
SDS-PAGE transferred to Hybond membrane (Amersham) 
and probed with appropriate primary and HRP-conjugated 
secondary (Sigma) Abs. Quantitation was performed using 
Image Lab 4.10 (Bio-Rad). For immunoprecipitation, 
Triton-X100 was replaced by 1% NP-40. After 
preclearing, cell extracts were incubated overnight with 
the indicated Abs or agarose beads-conjugated anti-Myc-
tag Ab (Sigma). Beads were further washed with the lysis 
buffer and precipitates were eluted in 4X Laemmli buffer 
prior to immunoblotting.
Subcellular Fractionation 
Nuclear, membrane and cytoplasmic fractions were 
prepared using the Subcellular Protein Fractionation 
Kit for Cultured Cells (Thermo Scientific) as per 
manufacturer’s instruction. Protein concentration was 
quantitated using the BCA protein assay kit (Pierce). 
GST pull-down assay
Expression of the Glutathione S-transferase (GST) 
fusion proteins was induced with 500μM isopropyl-β-
thiogalactopyranoside (IPTG). Fusion proteins were 
purified from bacterial lysates using gluthatione-
Sepharose 4B beads (GE Healthcare). Proteins extracts 
from NIH3T3 stable cell lines were incubated 2 hours 
with fusion proteins bound to gluthatione-Sepharose 
4B beads. Precipitates were recovered as described 
for immunoprecipitation assay and analysed by 
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immunoblotting.
Luciferase reporter assay
293T cells were seeded in 12-well dishes 24h prior to 
transfection using JetPrime (Polyplus) with Vav constructs, 
Top-firefly or Fop-firefly negative control luciferase 
plasmids (Millipore) and Renilla luciferase plasmid under 
the control of SV40 promoter, pRL(Promega). 48h after 
transfection, cell lysis was performed using the Passive 
Lysis buffer followed by the Dual luciferase assay 
(Promega). Firefly and Renilla luciferase activities were 
monitored following manufacturer’s instructions. LiCl 
(30mM) treatment was applied 3 hours before lysis. Top-
firefly luciferase values were normalized to the respective 
Renilla and Fop-luciferase values for each treatment.
Immunofluorescence
Cells were fixed in paraformaldehyde (4%) and 
permeabilised with 0.25% Triton-X100 in PBS. Cells 
were stained with the indicated Abs. Actin filaments were 
visualized with Alexa 546- or Alexa 647-conjugated-
phalloidin. Confocal images were acquired under a BD 
Pathway 855 Bioimaging System with a 40x objectif and 
further analysed using AttoVision and Image J softwares. 
Rac1 Activation Assay
Rac1 activation assays were performed using the 
Active Rac1 Pull-Down and Detection Kit. The assay 
consists on a GST-pull down experiment with the p21-
binding domain of PAK1 that selectively precipitates 
active Rac1 from whole cell extracts. Active Rac1 is 
quantified by immunoblot analysis using anti-Rac1 
monoclonal Ab (Thermo Scientific Pierce).
Statistical analysis
Statistical significance was assessed using impaired 
Student’s t test (Prism5.0, Graph Pad Software). P values 
<0.05 were considered significant with the following 
degrees: *p<0.05; **p<0.01; ***p<0.001.
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